Figure 1
![Figure 1. Approach to therapy of MDS patients. Consider erythroid-stimulating agents in any patients with baseline (erythropoietin) less than 500 mIU/mL; add low-dose granulocyte colony-stimulating factor if no response after 8 weeks of therapy (especially if RARS [refractory anemia with ringed sideroblasts]). Consider iron chelation in selected lower-risk chronically transfused patients. DNAMTI indicates DNA methyl transferase inhibitors; and RIC, reduced intensity conditioning. Professional illustration by Debra T. Dartez.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/113/25/10.1182_blood-2008-09-038935/4/zh89990937760001.jpeg?Expires=1735839139&Signature=Qz7fO3WApw9RvSgw83c4KDkrEYoKdXthnqthBnAcfd-4hs-kRz3Kh5dvgaOgWBjPysEhcFsyZtjZ28fSoa0xygsS9AWHTtVaZaKAWQyaZf2gZuskIBVMqRNRKiB4NVAdU5LyfWo6yKhpin5olAxfB-sjsNjUb~Sd0IA3eVCe5ESbMkje1y81zhvG~vlf747ZlQFilUzYJhnlprbOLtEDbnZue5NN1XWpeIgtgUPj1gDzQBB9b2yrfxN~sEqtL~iDtOzT~tPG2PWCMcm~u3lbhtvRT86ET4uhTSFmlcxrYEeyTCwh1GZX2tJtCYOUlajCfeBEVJ0mQUte2px9Z016RA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Approach to therapy of MDS patients. Consider erythroid-stimulating agents in any patients with baseline (erythropoietin) less than 500 mIU/mL; add low-dose granulocyte colony-stimulating factor if no response after 8 weeks of therapy (especially if RARS [refractory anemia with ringed sideroblasts]). Consider iron chelation in selected lower-risk chronically transfused patients. DNAMTI indicates DNA methyl transferase inhibitors; and RIC, reduced intensity conditioning. Professional illustration by Debra T. Dartez.
